Recently, data evaluating the real-world use of an FGFR1/2/3 inhibitor in patients with cholangiocarcinoma (#CCA) were published in The Oncologist Journal. Learn more. https://bit.ly/3NqtxBh
About us
The Incyte Medical showcase page shares scientific information about Incyte's product portfolio, molecular targets and disease states under investigation, as well as emerging clinical data. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & Autoimmunity. See our Community Guidelines: bit.ly/2sV0H5W Content is intended for US healthcare professionals.
- Website
-
https://www.incytemi.com/
External link for Incyte Medical
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
Updates
-
Check out a recent publication in Skin Health and Disease evaluating the long-term safety and efficacy of a topical JAK1/JAK2 inhibitor in patients with #vitiligo. https://bit.ly/4gXMSHj
Check Out a Recent Publication
-
Recently, the interim analysis of a single-arm, multicenter, Phase 2 study investigating a JAK1/JAK2 inhibitor in pediatric patients with treatment-naive or corticosteroid-refractory chronic graft-versus-host disease (#GVHD) was published in The Lancet. Learn more. https://bit.ly/3ZYoyyV
New Data in Pediatric Chronic GVHD
-
Assess your understanding of atopic dermatitis by considering how you would approach this hypothetical situation. #NationalEczemaAwarenessMonth https://bit.ly/4eGXMiS
-
A plain language summary (PLS) of the MAJIC-PV study has been published in Future Oncology. Learn more about a JAK1/JAK2 inhibitor for the treatment of patients with polycythemia vera (PV). https://bit.ly/3TNAuQ7
Read our Publication on Patients with PV
-
Urticaria, also known as hives, is a disease characterized by the development of raised, itchy pale red bumps on the skin. How much do you know about urticaria? #WorldUrticariaDay https://bit.ly/47R1mEF
-
Cholangiocarcinoma (#CCA) is a rare, aggressive form of cancer. Test your knowledge as we raise awareness of CCA and reinforce our commitment to patients and all of those impacted by rare cancers. #RareCancerDay https://bit.ly/3XLtDrE
Rare Cancer Day
-
We enjoyed our time at the 2024 European Academy of Dermatology and Venereology Congress in Amsterdam. Visit our website to learn more about the data we presented. #EADV2024 https://bit.ly/3XXZPcN
Incyte at EADV 2024
-
We're excited to present our latest dermatology research at the 2024 European Academy of Dermatology and Venereology Congress in Amsterdam. Read the latest press release to learn more about the data we plan to present at #EADV2024. https://bit.ly/3ZxPdCE
This content isn’t available here
Access this content and more in the LinkedIn app
-
Findings from the Phase 2 AGAVE-201 study of an anti-CSF-1R antibody in patients with chronic graft-versus-host disease (#GVHD) were published in The New England Journal of Medicine. Learn more. https://bit.ly/3MQ2jDG
Chronic GVHD Data Published in NEJM